Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Cholesterol-Lowering Program
Brain Injury Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
ASX Announcements
Filter by Year:
2023
2022
2021
2020
18-Nov-2022
Nyrada Receives A$1.2M R&D Tax Incentive Rebate
27-Oct-2022
CEO Remuneration Update
26-Oct-2022
Quarterly Activities Report and Appendix 4C
18-Oct-2022
2022 AGM Letter to Shareholders and Proxy
18-Oct-2022
2022 AGM Notice of Meeting and Proxy
10-Oct-2022
Efficacy Study Published in Journal of Lipid Research
29-Sep-2022
Presentation to ShareCafe Hidden Gems Webinar
5-Sep-2022
Presentation to E&P Small Caps Health Care Conference
29-Aug-2022
Nyrada Reports Full Year FY2022 Results
29-Aug-2022
Annual Report to June 30 2022
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Next
